OncoCyte (OCX) Set to Announce Quarterly Earnings on Tuesday

OncoCyte (NASDAQ:OCX) will announce its earnings results after the market closes on Tuesday, November 12th.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

OncoCyte Stock Performance

OCX stock opened at $2.84 on Thursday. The company has a fifty day moving average of $3.06 and a 200-day moving average of $2.96. OncoCyte has a one year low of $2.08 and a one year high of $4.34.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. StockNews.com initiated coverage on OncoCyte in a research note on Saturday, November 2nd. They set a “sell” rating for the company. Needham & Company LLC reiterated a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, OncoCyte currently has a consensus rating of “Hold” and a consensus target price of $4.06.

Insiders Place Their Bets

In other news, CFO Andrea S. James bought 33,670 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the purchase, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the acquisition, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrea S. James acquired 33,670 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. 1.58% of the stock is currently owned by insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.